Altogether, our study sheds light not only on anti-PD-1/PD-L1 resistance in cSCC, HNSCC, and melanoma patients but also on potential biomarkers to predict the response to this therapy and possible alternative treatments for these diseases. This evidence concerns the gene CD274 and skin squamous cell carcinoma.